- Home
- SDHC vs INVA Comparison
SDHC vs INVA Comparison
Compare SDHC & INVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SDHC
- INVA
- Stock Information
- Founded
- SDHC 2008
- INVA 1996
- Country
- SDHC United States
- INVA United States
- Employees
- SDHC N/A
- INVA N/A
- Industry
- SDHC
- INVA Biotechnology: Pharmaceutical Preparations
- Sector
- SDHC
- INVA Health Care
- Exchange
- SDHC Nasdaq
- INVA Nasdaq
- Market Cap
- SDHC 1.5B
- INVA 1.2B
- IPO Year
- SDHC 2024
- INVA 2004
- Fundamental
- Price
- SDHC $32.31
- INVA $18.25
- Analyst Decision
- SDHC Hold
- INVA Buy
- Analyst Count
- SDHC 6
- INVA 1
- Target Price
- SDHC $32.80
- INVA N/A
- AVG Volume (30 Days)
- SDHC 64.4K
- INVA 684.8K
- Earning Date
- SDHC 12-24-2024
- INVA 11-06-2024
- Dividend Yield
- SDHC N/A
- INVA N/A
- EPS Growth
- SDHC N/A
- INVA 46.55
- EPS
- SDHC 4.71
- INVA 0.99
- Revenue
- SDHC $905,304,000.00
- INVA $352,745,000.00
- Revenue This Year
- SDHC $26.92
- INVA $16.20
- Revenue Next Year
- SDHC $15.20
- INVA N/A
- P/E Ratio
- SDHC $6.82
- INVA $18.62
- Revenue Growth
- SDHC 17.46
- INVA 21.46
- 52 Week Low
- SDHC $20.55
- INVA $14.33
- 52 Week High
- SDHC $39.50
- INVA $21.28
- Technical
- Relative Strength Index (RSI)
- SDHC 43.58
- INVA 34.59
- Support Level
- SDHC $31.04
- INVA $18.33
- Resistance Level
- SDHC $33.02
- INVA $18.69
- Average True Range (ATR)
- SDHC 0.93
- INVA 0.33
- MACD
- SDHC -0.05
- INVA -0.05
- Stochastic Oscillator
- SDHC 32.26
- INVA 13.61
About SDHC Smith Douglas Homes Corp.
Smith Douglas Homes Corp is a company engaged in the design, construction, and sale of single-family homes in some of the highest growth and desirable markets in the Southeastern United States. The company has organized into five geographical segments so their reportable segments include Atlanta, Raleigh, Charlotte, Nashville, and Alabama which consists of both Birmingham and Huntsville.
About INVA Innoviva Inc.
Innoviva Inc is a company with a portfolio of royalties and innovative healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.